Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCD-261 in moderate to severe ulcerative colitis
NCT07080034Phase 2Recruiting
- Sponsor
- BIOCAD
- Start
- Aug 2025
- Primary completion
- Jan 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of BCD-261 in ulcerative colitis (UC), sponsored by BIOCAD. Started Aug 2025; status: recruiting.
02
Drugs
BCD-261
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07080034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07080034.